CHICAGO -- A toxin secreted by Vibrio vulnificus, a water and food-borne bacteria that can cause rapidly lethal infections in persons with liver disease, has potential to prevent the growth of tumors, according to a new study by Northwestern Medicine scientists.
Karla Satchell, a professor in microbiology-immunology at Northwestern University Feinberg School of Medicine, and her team demonstrated in a paper in Nature Communications, that a multifunctional-autoprocessing repeats-in-toxin (MARTX) protein from Vibrio vulnificus can inhibit tumor cell growth by cutting the protein Ras. This protein is central to cell division and survival, and mutations in the gene that codes for Ras are a common cause of human malignancies.
'Ras is important for cell proliferation in cancer, so the toxin could potentially be developed as a treatment for different types of tumors,' Satchell said. 'It has been known that Ras has a role in cancer development and targeting Ras has been one of the hardest challenges of cancer research and drug discovery.'
Ras also plays a role in detecting pathogens and activating an immune response. The bacterium uses the MARTX toxin protein to inactivate Ras, increasing its own virulence and allowing it to spread throughout the host.
They used cell biological, genetic and biochemical techniques to show how a specific part of the toxin, an effector domain called DUF5Vv, targets and cleaves Ras. Satchell's team also revealed the ability of this domain to slice both normal and mutant forms of Ras commonly found in cancers.
'What is unique about this study is the ability of the toxin to cleave Ras, rather than modify it, which is a novel mechanism for inactivating Ras,' Satchell said.
The scientists plan to continue to study the mechanisms and biochemistry of the MARTX toxin specificity to the Ras protein.
The research was funded by National Institutes of Health grants R01AI051490, R01AI092825, R01AI098369, R01CA152601, R01CA152799, R01CA168292 and a Northwestern University Avon Center of Excellence grant and by the Northwestern Medicine Catalyst Fund.